PERIFLOW: Establishing a New Protocol for Early Mucositis and Peri-implantitis Treatment Using an Air-polishing Device

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03348111
Collaborator
(none)
0
1
1
24
0

Study Details

Study Description

Brief Summary

Considering the frequent occurence of peri-implantitis and mucositis, a multiple of treatment alternatives have been proposed including non-surgical and surgical procedures. However, it seems that the most effective treatment remains prevention of these diseases.

The aim of this study is to emphasize on mucositis and peri-implantitis prevention using an air abrasion device the Air-Flow Master Piezon® with erythritol and chlorhexidine powder in order to eliminate and / or disorganize the biofilm responsible for peri-implant mucosa inflammation.

Condition or Disease Intervention/Treatment Phase
  • Device: Air-polishing device
N/A

Detailed Description

Peri-implant infections (mucositis and peri-implantitis) depict an increasing focus in dental practice and implantology. mean prevalence of mucositis is of 43% and periimplantitis of 22%. Consequences for the implant without successful treatment range from local reversible inflammation (mucositis) to implant loss (periimplantitis). These lead to functional, social and esthetic prejudices for patients. The main factor for establishment of peri-implant infections is the formation and maturation of the bacterial biofilm. Peri-implantitis and mucositis treatment require the removal of the bacterial biofilm and the disinfection of the implant surface. Because of special surface conditions and structures, it is more difficult to remove bacterial biofilms from implant surfaces than teeth. the key to controlling the inflammation due to the bacterial biofilm is to prevent its installation and progression. The procedure tested in this study is an air abrasion device, the Air-Flow Master Piezon® with erythritol and chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally by disorganizing and eliminating the biofilm. Follow-up of the patients will be held every 2 months for 6 months by scoring the bleeding on probing, the plaque index and measuring clinical attachment level in order to compare it with the initial measure. At 6 month an X-ray will also enable to compare bone level and mineralization. This initial study will help establish a standardized protocol for peri-implant infection management.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Establishing a New Protocol for Early Mucositis and Peri-implantitis Treatment Using an Air-polishing Device
Anticipated Study Start Date :
Jun 1, 2019
Anticipated Primary Completion Date :
Jun 1, 2021
Anticipated Study Completion Date :
Jun 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Air-polishing device

Air polishing of the implant surface and/or elimination of the intrapocket biofilm using the air abrasion device Air-Flow Master Piezon®

Device: Air-polishing device
Air abrasion using the Air-Flow Master Piezon® with erythritol and Chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally
Other Names:
  • Air-Flow Master Piezon®
  • Outcome Measures

    Primary Outcome Measures

    1. Change from baseline peri-implant inflammation at 6 months [6 months]

      bleeding on probing (binary criteria : yes/no)

    2. Change from baseline peri-implant inflammation at 4 months [4 months]

      bleeding on probing (binary criteria : yes/no)

    3. Change from baseline peri-implant inflammation at 2 months [2 months]

      bleeding on probing (binary criteria : yes/no)

    Secondary Outcome Measures

    1. stability of the bone level [6 months]

      bone level assessed by X-ray

    2. clinical attachment gain [2 months]

      The measurement of the probing depth and of the eventual recession (compared to Baseline) allows to assess the clinical attachment gain

    3. clinical attachment gain [4 months]

      The measurement of the probing depth and of the eventual recession (compared to Baseline) allows to assess the clinical attachment gain

    4. clinical attachment gain [6 months]

      The measurement of the probing depth and of the eventual recession (compared to Baseline) allows to assess the clinical attachment gain

    5. Quality of life with Oral Health Assessment Tool (OHAT) [6 months]

      The Oral Health Assessment Tool (OHAT) was a component of the Best Practice Oral Health Model for Australian Residential Care study. The OHAT provided institutional carers with a simple, eight category screening tool to assess residents' oral health, including those with dementia

    6. Quality of life with the Geriatric Oral Health Assessment Index (GOHAI) [6 months]

      The Geriatric Oral Health Assessment Index (GOHAI) is a self-reported measure designed to assess the oral health problems of older adults

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • adult patients,

    • possessing one or more implants prosthetically engaged with local peri-implant mucosa inflammation assessed by bleeding on probing

    • affiliated with a social security scheme

    Exclusion Criteria:
    • patients with implant mobility or implants associated with vestibular cellulitis

    • not available patients for the follow-up visits

    • patients with known allergy to erythritol and/or Chlorhexidine powder

    • patients with chronic bronchitis

    • patients with asthma

    • patients with endocarditis

    • patients with contagious disease

    • patients with immunodeficiency

    • patients under radiotherapy and/or chemotherapy and/or antibiotics

    • not mastery of plaque control on the part of the patient (after education)

    • subjects under legal protection

    • pregnant or breastfeeding women

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Toulouse (Faculty of Dental Surgery) Toulouse France 31059

    Sponsors and Collaborators

    • University Hospital, Toulouse

    Investigators

    • Principal Investigator: Sara Laurencin, MD, University Hospital of Toulouse

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Toulouse
    ClinicalTrials.gov Identifier:
    NCT03348111
    Other Study ID Numbers:
    • RC31/15/7854
    • 2016-A00754-47
    First Posted:
    Nov 20, 2017
    Last Update Posted:
    Aug 26, 2020
    Last Verified:
    Aug 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Toulouse
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 26, 2020